SEC Form 3
FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 12/09/2021 | 3. Issuer Name and Ticker or Trading Symbol Future Health ESG Corp. [ FHLTU ] | |||||||||||||
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Class A Ordinary Share, par value $0.0001 per share | 3,512,288(1) | I | By Barclays Bank PLC |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Redeemable Warrants | (2) | (2) | Class A Ordinary Share | 1,756,144 | 11.5 | I | By Barclays Bank PLC |
Explanation of Responses: |
1. Beneficially owned Class A ordinary shares and redeemable warrants are comprised in Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant |
2. The redeemable warrants will become exercisable on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the initial public offering of the issuer's securities. The redeemable warrants will expire five years after the completion of the issuers initial business combination or earlier upon redemption by or liquidation of the issuer, as described in the prospectus for the issuer's initial public offering. |
Remarks: |
Name of person filing: Barclays PLC Barclays Bank PLC (controlled by Barclays PLC) Address of Principal Business Office or, if none, Residence: Barclays PLC 1 Churchill Place London, E14, 5HP, England Barclays Bank PLC 1 Churchill Place London, E14, 5HP, England |
Suejean Mott | 12/13/2021 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |